樂觀
$30.64
情境價格
$18.900
-0.344 (-1.82%)收盤時
Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.
Stevanato Group (STVN) is currently priced at $18.90, which is below several analyst price targets, including $22 from Deutsche Bank and $25 from TD Cowen. However, the stock has a low RSI of 18.47, indicating it is oversold, but it also has a significant risk with a 1-year change of -26.91%. This suggests that while there may be potential for recovery, the stock is currently under pressure and may not be a strong buy at this moment.
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Stevanato (STVN) Q2 2026 Earnings Call Transcript

Stevanato Group Reports Strong Q2 Earnings with Strategic Divestiture

Stevanato Group Divests California Subsidiary Balda C. Brewer, Inc.

Stevanato Group Secures European Approvals for New Injector Therapies

Stevanato Group to Release Q2 2026 Financial Results
Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).
Stevanato Group (STVN) is currently priced at $18.90, which is below several analyst price targets, including $22 from Deutsche Bank and $25 from TD Cowen. However, the stock has a low RSI of 18.47, indicating it is oversold, but it also has a significant risk with a 1-year change of -26.91%. This suggests that while there may be potential for recovery, the stock is currently under pressure and may not be a strong buy at this moment.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。